Summary of findings 1: Efficacy and safety of IVT lampalizumab 4‐weekly (monthly) vs sham
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham (low certainty).
- RR 1.77 [0.73, 4.3]3 studies · 1330 participantsLow